Intellia Therapeutics (NTLA) Tops Q3 EPS by 5c
Tweet
Share
E-mail
Get Alerts NTLA Hot Sheet
Join SI Premium – FREE
Intellia Therapeutics (NASDAQ: NTLA) reported Q3 EPS of ($1.34), $0.05 better than the analyst estimate of ($1.39). Revenue for the quarter came in at $9.11 million versus the consensus estimate of $8.28 million.
For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- American Outdoor Brands (AOUT) Tops Q4 EPS by 14c
- Reformation Inc. files for IPO on NYSE under ticker REF
- Select Water Solutions and ISE Chemicals agree on iodine extraction deal
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
